| Code | CSB-RA022812MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US10233255B2, targeting Signal Transducer and Activator of Transcription 3 (STAT3). STAT3 is a critical transcription factor that mediates cellular responses to cytokines and growth factors, regulating essential biological processes including cell proliferation, differentiation, apoptosis, and immune responses. Upon activation by phosphorylation, STAT3 dimerizes and translocates to the nucleus where it modulates gene expression. Aberrant STAT3 activation is implicated in numerous malignancies including breast, lung, and prostate cancers, as well as inflammatory disorders and immune dysregulation, making it a significant target for therapeutic and diagnostic research.
The reference antibody patent describes monoclonal antibodies with specific binding characteristics to STAT3, designed for research and potential therapeutic applications. This biosimilar antibody provides researchers with a reliable tool for investigating STAT3 signaling pathways, examining its role in oncogenesis and inflammation, and exploring potential therapeutic interventions targeting this pathway in various disease models.
There are currently no reviews for this product.